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Abstract 
We have developed a rapid and robust method for the determination of urea in spent 
haemodialysis fluid, as a measure of the efficiency of haemodialysis treatments. A 
novel flow analysis instrument (which generates a pulsed solution flow) was coupled 
with a chemiluminescence detection system, based on the oxidation of urea with the 
hypobromite anion. The ‘Pulsed-Flow Chemiluminescence Analyser’ exhibited high 
precision (1.6% RSD for a 10-5 M urea standard) and detectability (9  10-7 M, 
S/N = 3) as a result of the rapid and reproducible mixing of small volumes of reagent 
and sample at the point of detection. The proposed chemiluminescence technique and 
an established urease-based laboratory procedure were compared, and showed a very 
similar trend for the change in urea concentration during a typical haemodialysis 
treatment. The relative chemiluminescence response from the oxidation of species 
with similar structure has revealed the inherent selectivity of the light producing 
pathway, but a positive interference was obtained from protein when this technique 
was applied to the determination of urea in serum samples. The -amino acid arginine 
was identified as the predominant source of this interference. 
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Introduction 
Urea is used as a marker for the low-molecular-mass toxins removed during the 
haemodialysis treatments received by patients with chronic renal failure. It has been 
demonstrated that a high urea clearance correlates with long-term patient survival [1]. 
Patients with stable end-stage renal failure may require haemodialysis lasting 3 to 6 
hours on 2 or 3 days per week [2]. The efficiency of this treatment has traditionally 
been determined by subjective assessments of the patient’s well-being, and an 
evaluation of pre- and post-dialysis blood biochemistry, with samples taken on a 
monthly basis. In 1995, it was recommended a target blood urea reduction of at least 
55% for patients dialysing three times per week, and 85% for patients receiving 
biweekly dialysis treatments [1]. Whilst the modelling of patients’ urea levels based 
on the determination of this species in plasma or serum samples remains popular, the 
direct measurement of the urea transferred to the electrolyte solution (dialysate) 
pumped along the opposing side of the semipermeable membrane is a convenient 
alternative that can also provide feedback during the course of the dialysis treatment 
[1]. 
The dominant methodology for the determination of urea in clinical laboratories 
involves the selective urease-catalysed hydrolysis of urea, followed by the 
determination of ammonia with colorimetry or electrochemistry, or after further 
enzyme catalysed reactions [3]. Other techniques, such as the colorimetric reaction 
between urea and diacetyl monoxime, remain in use, particularly for matrices that 
contain urease inhibitors [4]. In relation to monitoring haemodialysis, Koncki and 
co-workers recently discussed a variety of methods proposed for the determination of 
urea in spent dialysate [5]. Each of the discussed methods incorporated immobilised 
urease, and most used conductometric or potentiometric detection of the ammonia 
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produced by the hydrolysis of urea. Koncki et al. noted that ammonium sensors and 
ammonium-based biosensors exhibit cross-sensitivity to alkali ions (particularly 
potassium) removed from the blood during dialysis, which they addressed with the 
use of a reference cell detector [5]. However, it has been reported that there is a poor 
uptake of proposed spent-dialysate urea sensors for clinical diagnosis [6]. Della Ciana 
and Caputo ascribed this lack of acceptance to problems with sample handling, 
instrument calibration, the cost of manufacture and quality control. In addition, there 
have been issues of instrumental reliability related to the “bedside” environment 
found in the practice of haemodialysis [6]. 
Pulsed flow chemistry, first reported by Wang and co-workers [7] in 1998, has been 
shown to be a viable alternative for automated analyses, combining the high 
sensitivity and precision of existing flow-based techniques with robust, small-scale 
instrumentation [7,8]. Solutions are propelled by the generation of short pressure 
pulses to produce precisely-timed bursts of liquid flow, interspersed with relatively 
longer periods when the solution remains static. Analysis modes are interchangeable 
using software settings, without physical alteration of the instrument manifold [7,8]. 
In a previous study we demonstrated the suitability of this instrumentation for 
chemiluminescence detection and applied this approach to the determination of 
molecules of clinical and forensic importance [8]. The appeal of chemiluminescence 
as a method of detection stems from its high sensitivity, wide detection ranges and, in 
some cases, excellent selectivity observed for the desired analytes [9]. 
In our recent review of methodology for the determination of urea, particular attention 
was given to approaches that employed chemiluminescence detection [4]. With one 
exception [10], the chemiluminescence-based techniques have incorporated the use of 
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urease and conversion of the hydrolysis products by further enzymatic reactions [11-
14] or ion-exchange [15], to form, release or remove, the limiting species in a 
chemiluminescent reaction. The feasibility of each technique was demonstrated with 
preliminary testing of plasma [12,14], serum [11-13], urine [12,15] and dialysate [14] 
samples. 
Whilst the above procedures exhibited adequate sensitivity, analytical methodology 
incorporating a direct chemiluminescence reaction would greatly reduce instrument 
complexity and reagent cost, which are particularly important factors for point-of-care 
urea monitoring. The only direct reaction with urea reported in the literature to exhibit 
significant chemiluminescence is the oxidation by hypohalites, first described by 
Stauff and co-workers in 1962 [16,17]. Hu et al. independently examined this 
chemistry and, in 1994, published a flow-injection technique for the determination of 
urea in urine based on the reaction between urea and hypobromite [10]. The only 
significant interferent present in the matrix was ammonia, although this species 
produced an emission at 200-fold lower intensity than that of urea, and was removed 
with on-line cation exchange [10]. Nevertheless, the determination of urea in urine is 
no longer considered important in clinical diagnosis and monitoring, other than for a 
crude estimation of overall nitrogen balance [18,19]. 
In this paper we present simple, robust and selective methodology for the 
determination of urea, using novel pulsed-flow instrumentation coupled with 
chemiluminescence detection based on the reaction with alkaline hypobromite. The 
application of this methodology to the rapid determination of urea during the course 
of a haemodialysis treatment is demonstrated, and the potential for on-line monitoring 
is discussed. 
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Experimental 
Flow Injection Instrumentation 
A conventional flow injection analysis manifold was assembled (Figure 1(i)) using a 
syringe pump (Model sp210iw, World Precision Instruments, Glen Waverly, Victoria, 
Australia) or peristaltic pump (Gilson Minipuls 3; John Morris Scientific, Balwyn, 
Victoria, Australia) with bridged PVC tubing (Protech Group, Coolum Beach, 
Queensland, Australia) to propel solutions through 0.8 mm i.d. PTFE tubing 
(Protech). Solution lines were combined with a Y-piece, samples were injected into 
the carrier stream via an automated 6-port valve (Valco Instruments, Schenkon, 
Switzerland), and detection was achieved using a custom built flow-through 
luminometer. The luminometer consisted of a coiled flow cell (PTFE tubing, Protech) 
mounted flush against the window of a photomultiplier tube (PMT; Thorn-EMI Model 
9924SB, Ruislip, Middlesex, UK) which was operated at 900 V provided by a stable 
power supply (Model PM28BN, Thorn-EMI) via a voltage divider (C611, Thorn-
EMI). The flow cell, PMT and voltage divider were encased in a padded light-tight 
housing, and the output from the photomultiplier was documented with a chart 
recorder (YEW Type 3066, Yokogawa Hokushin Electric, Tokyo, Japan). 
Pulsed-Flow Instrumentation 
The two-line Pulsed-Flow Chemiluminescence Analyser (Figure 1(ii)) consisted of a 
prototype pulsed flow chemistry module (Model C, Precision Devices, Shoreham, 
Victoria, Australia) and PMT (Thorn-EMI, Model 9924SB) with custom built 
housing. Improvement in the design of this instrument compared to that used in our 
previous study [8] included a detection cell constructed by machining a coiled flow 
pathway from a transparent acrylic block and fixing a thin film of the same material to 
enclose the coil. This modification reduced the pulse dampening by the  flexible 
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tubing used to join instrument components to the previously used glass flow cell. To 
eliminate light piping through the solution lines, the plastic casing was altered to 
include sealable compartments for the sample, reagent and waste containers. A 
number of pulse sequences were examined. The most suitable sequence contained 
pulses of the sample solution to flush the sample line and detection cell, a single pulse 
consisting entirely of reagent solution, followed by a final pulse of sample solution. 
The output from the PMT was documented with a chart recorder (YEW Type 3066). 
Chemiluminescence Emission Spectra 
A Cary Eclipse spectrofluorimeter (Varian Australia, Mulgrave, Victoria, Australia), 
fitted with a R928 photomultiplier tube (Hamamatsu, Iwata-gun, Shizuoka-ken, 
Japan) was adapted for the measurement of chemiluminescence spectra with a 
two-line continuous flow manifold incorporating an integrated glass Y-piece and 
spiral flow cell (0.5 mm i.d., 90 L volume, Embell Scientific, Murwillumbah, NSW, 
Australia) placed in front of the emission window of the spectrofluorimeter. A 
peristaltic pump with silicone pump tubing was used to continuously pump reagent 
and analyte solution through 0.5 mm i.d. PTFE tubing to the flow cell where the 
chemiluminescence reaction occurred (Figure 1(iii)). The excitation source of the 
spectrofluorimeter was turned off (Bio/Chemiluminescence data mode) and the final 
data recorded was an average of ten scans (1000 ms gate time, 1 nm data interval) 
with a slit width of 20 nm. Emission spectra were corrected for the wavelength 
dependence of the detector response and monochromator transmission by 
multiplication with a correction factor that was established using a 45 W quartz-
halogen tungsten coiled lamp of standard spectral irradiance (OL245M, Optronics 
Laboratories, Orlando, FL, USA). The lamp was operated at 6.5 A d.c. supplied by a 
programmable constant current source (OL65A, Optronics Laboratories). 
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Reagents and Clinical Samples 
Solutions of hypobromite were prepared by disproportionation of bromine (Hopkin & 
Williams, Chadwell Heath, Essex, UK) in cold aqueous sodium hydroxide (AR grade; 
Ajax (APS), Auburn, NSW, Australia) in a capped Schott bottle with stirring. After 
preparation, solutions were stored in Schott bottles covered with aluminium foil to 
prevent photodegradation of the hypobromite reagent [20]. For an examination of the 
relationship between the chemical structure of the reactant and chemiluminescence 
intensity, ammonium chloride (AR; BDH, Poole, Dorset, UK), urea (AR; Ajax), 
ammonium carbamate (LR; Pfaltz & Bauer, Waterbury, CT, USA), ammonium 
hydrogen carbonate (98%; Riedel-de Haën, Seelze, Germany), uric acid (98%; BDH), 
hydrazinium sulfate (LR; Ajax), methylurea (97%; Sigma-Aldrich, Castle Hill, NSW, 
Australia), guanidine hydrochloride (AR; Sigma-Aldrich), thiourea (LR; BDH), 
sulphamide (99%; Sigma-Aldrich), creatine (LR; Ajax), methylammonium chloride 
(LR; Ajax), hydroxylamine hydrochloride (LR; Ajax), and acetamide (LR; Ajax) 
solutions were each prepared by dissolution of the solid in deionised water followed 
by the appropriate dilutions, with the exception of ammonium carbamate which was 
dissolved in a sodium hydroxide (0.1 M) solution to improve stability. Formamide 
(99.5%; BDH) was purchased as a liquid and diluted with water as required. Solutions 
of the L-amino acids; alanine, aspartic acid, glycine, histidine, isoleucine, lysine, 
phenylalanine, serine, threonine, valine (each purchased from Sigma), asparagine 
monohydrate, glutamine, leucine, methionine (Calbiochem, La Jolla, CA, USA), 
glutamic acid (sodium salt), proline (BDH), tryptophan, tyrosine (Aldrich), arginine 
(Ajax) and cysteine (Hopkin & Williams) were prepared by dissolution of the solid in 
deionised water. 
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Spent dialysate was periodically collected from the waste line of a Fresenius 
Polysulfone Capillary Dialyser (Hemoflow F-series High Performance Steam, 
Fresenius Medical Care, Bad Homburg, Germany) during a single haemodialysis 
treatment performed in the Dialysis Unit of the Geelong Hospital. 
Serum samples were prepared by centrifugation of whole blood (obtained from the 
Geelong Hospital) in a Vacutainer tube (L10259-00, Becton Dickinson, Franklin 
Lakes, NJ, USA) containing a clot activator. The removal of protein from the serum 
samples was achieved by filtering 5 mL of the sample solution through the 
polyethersulfone membrane contained in a Vivaspin Concentrator (Product numbers 
VS2001 and VS2021, with a relative-molecular-mass cut-off of 10000 and 30000 
g mol-1; VivaScience, Westford, MA, USA) by centrifugation until a constant volume 
was reached. 
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Results and Discussion 
Preliminary Studies with Conventional Flow Injection Instrumentation  
Using a conventional two-line flow injection manifold (Figure 1(i)) with the reagent 
conditions established by Hu and co-workers, we observed a detection limit (S/N = 3) 
of 2  10-7 M urea and an optimum flow rate of 5 mL min-1. The previous group 
reported a detection limit (3) of 9  10-8 M at an optimum flow rate of 10 mL min-1. 
The differences are most likely due to the variation in instrumental design, 
particularly as the previous researchers used a purpose-built double concentric flow 
cell [10]. As the concentration of urea in spent dialysate or blood is over four orders 
of magnitude greater than our detection limit, the difference in reported detectability 
for the two studies is insignificant in the context of these sample matrices. 
The decomposition of hypobromite, to form bromide, bromite and bromate ions and 
molecular oxygen, occurs at a rate which is greatly influenced by the hypobromite 
concentration, the pH and temperature of the solution, and the intensity of light to 
which the solution is exposed [20,21]. Concerns have been raised about the use of 
alkaline hypobromite solutions as analytical reagents [20,22]. We examined the 
stability of a hypobromite solution (0.08 M) that was prepared by adding bromine 
(200 L) to a sodium hydroxide solution (50 mL, 0.4 M). Syringe pumps were used to 
propel the solutions through the two-line FIA manifold (Figure 1(i), line 1: 
hypobromite solution (0.08 M), line 2: H2O carrier, 5 mL min-1 each line) to eliminate 
the flow-rate variation associated with peristaltic pump tubing elasticity, which leads 
to variations in signal intensity, particularly over long periods of time [23]. Five 
replicate injections of a urea standard (1  10-5 M) were performed hourly for eight 
hours, and at three times the following day. No significant decrease in the 
chemiluminescence intensity (peak height) was observed, although some minor 
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variation in the signal and dark current response resulted in a RSD of around 3% for 
all injections. It was concluded that the hypobromite solution was stable for at least 
one day, and was prepared daily for all the following experiments. 
Pulsed-Flow Instrumentation 
The determination of urea with the Pulsed-Flow Chemiluminescence Analyser (Figure 
1(ii)) involved the placement of reagent (0.08 M hypobromite) and sample solution 
vials into compartments incorporated into the device and initiation of a programmed 
pulse sequence to transport the solutions to a mixing point and present the reacting 
mixture to a detection cell. Only one pulse (50 L) of reagent solution was required 
for each analysis cycle (after initial priming of the reagent line) and, consequently, the 
reagent vial did not require refilling during the testing period. After completion of the 
pulse sequence, the reacting mixture remained in the detection cell until the maximum 
emission was reached (approximately 1.5 s), which was documented with a chart 
recorder. Using the Pulsed-Flow Chemiluminescence Analyser with this procedure, 
the limit of detection (S/N = 3) was 9  10-7 M urea, and a relative standard deviation 
of 1.6% was calculated using 10 replicate analyses of a single urea standard solution 
(1  10-5 M). 
Analytical Selectivity 
In a study of the chemiluminescent oxidation of urea with alkaline hypobromite, Hu 
and co-workers examined the emission intensity for a variety of other species [10]. No 
chemiluminescence was detected when mixing hypobromite with alkylamines 
(1 mM), and a very weak emission was measured for a variety of carboxylic acids and 
amino acids (ca. 10 mM). Significant chemiluminescence was observed from the 
oxidation of humic acid, pyrogallol and ammonia. However, to achieve comparable 
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emission intensity with urea, the concentration of ammonia was over two orders of 
magnitude greater. 
At this stage the relationship between chemiluminescence intensity and the structure 
of the reactants remains unresolved. The emission intensity for the oxidation of urea 
with hypobromite was compared to that of species with similar structure (Table 1). 
Unlike procedures for the determination of urea based on the reaction with diacetyl 
monoxime [3], similar species with ureide functionality (as demonstrated by 
methylurea) do not strongly interfere. The solutions containing ammonia each 
produced a similar emission, which was over forty times lower in intensity than that 
observed for a 10 mM solution of urea. The spectral distribution of the 
chemiluminescence accompanying the oxidation of urea and ammonia with 
hypobromite was found (by the previous workers) to be significantly different [24], 
suggesting that the reaction pathways lead to two distinct emitting species. Therefore, 
the inherent features of each reaction, such as the spectral distribution and reaction 
kinetics, can be exploited to provide additional selectivity for one of these two 
species. By inserting a glass filter between the chemiluminescence reaction cell and 
the photomultiplier tube, Hu and co-workers [25] reduced the interference from both 
urea and humic acids for the determination of ammonia in rainwater and fogwater 
using flow injection analysis methodology. However, for the determination of urea in 
urine, cation exchange was used to remove the interference from ammonia [10]. In 
our study, the relative difference in chemiluminescence intensity for urea and 
ammonia was found to be greater at lower analyte concentrations and dependent on 
both the instrument manifold and the wavelength response of the detector. Compared 
to the analysis of urine, the determination of urea in spent dialysate is not complicated 
by a high endogenous ammonia concentration [3] and therefore the cation exchange 
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adopted by Hu and co-workers for the analysis of urine [10], was not necessary for the 
analysis of these samples. 
Determination of Urea as a Marker for Dialysis Efficiency 
The characteristics of the Pulsed-Flow Chemiluminescence Analyser – compact, 
robust and simple instrumentation – are ideal for on-site analysis. To demonstrate the 
potential of this methodology for bed-side monitoring of haemodialysis, urea was 
determined in spent dialysate samples, collected every 10 minutes from the waste line 
of a Fresenius Polysulfone Capillary Dialyser, over a 100 minute segment of a typical 
haemodialysis treatment performed at a local hospital. Each spent dialysate sample 
was analysed with the chemiluminescence method within two hours of collection and 
then stored in a refrigerator for analysis with an existing urease based technique the 
following day. High stability is observed for urea in clinical samples, if bacterial 
contamination is avoided [3]. 
Chemiluminescence assays were performed with the instrumental conditions 
discussed in the previous sections and with each sample diluted 100 fold with water. 
Nine urea standards (2.5  10-5 M to 2.0  10-4 M) were used to prepare a calibration, 
which closely approximated linearity (R2 = 0.9997, log-log gradient of 1.01). 
Enzymatic assays were performed at a pathology laboratory (Pathcare Consulting 
Pathologists, Geelong, Victoria, Australia) with the Dimension Clinical Chemistry 
System, based on reaction with urease and glutamate dehydrogenase, and monitoring 
NADH concentration with the dichromic (340, 383 nm) rate technique. 
No significant difference in chemiluminescence intensity was observed for urea 
standards prepared in water or the pre-dialysis electrolyte fluid prior to the 100-fold 
dilution in water performed on all standards and samples. The two techniques showed 
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a very similar trend for the change in analyte concentration (Figure 2). However, the 
results of the enzymatic analysis were consistently higher than those from the Pulsed-
Flow Chemiluminescence Analyser. Overestimation when using techniques based on 
the enzymatic breakdown of urea may result from endogenous ammonia, particularly 
in patients with impaired liver function [5], but it would be premature to conclude that 
this was the cause for the observed difference without more extensive investigation. A 
deliberate interruption in the dialysate flow resulted in a temporarily raised urea 
concentration in the spent dialysate sample collected at 80 minutes after the initiation 
of the haemodialysis treatment. It was therefore concluded that the pulsed-flow 
chemiluminescence analyser has the potential to provide a near-continuous measure 
of dialysis efficiency during treatment. The technique that we have presented has a 
number of distinct advantages including: a simple process consisting of a single 
chemical reaction performed with robust instrumentation; high analytical frequency 
(120 to 300 samples per hour); low reagent consumption (50 L per cycle); an 
inherent low response from endogenous ammonia; and the potential for on-line 
electrochemical generation of the reagent from a potassium bromide solution [26]. 
Determination of Urea in Serum 
The Pulsed-Flow Chemiluminescence Analyser was also applied to the determination 
of urea in human serum samples. The results from this technique were outside the 
normal reference levels for urea in serum (2.1 to 7.1 mM) [27], and significantly 
higher than those produced with a conventional enzymatic procedure. An albumin 
sample, prepared at a concentration of 60 g L-1 to simulate the total protein 
concentration in adult serum samples (60 to 80 g L-1, with around 30 to 50 g L-1 as 
albumin) [27], produced a signal comparable to the difference between the response 
from the chemiluminescence and enzymatic procedures. Centrifuge tubes containing a 
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polyethersulfone membrane with a molecular weight cut off (MWCO) of either 10000 
or 30000 g mol-1 were employed to remove the majority of the proteins contained in 
the serum sample, prior to analysis by both methods. After removal of the proteins, 
the results obtained with the proposed chemiluminescence method were in good 
agreement with those from the conventional enzymatic procedure (Table 2).  
The obsolete manometric determination of urea, based on the reaction of urea with 
hypobromite and measurement of the evolved nitrogen gas, was also subject to 
interference from protein in serum and plasma samples [28]. It was established that 
the arginine content of the protein was chiefly responsible for the additional 
production of nitrogen [29]. Interestingly, an examination of the chemiluminescence 
response from the reaction of hypobromite with twenty amino acids using the pulsed-
flow instrumentation revealed that arginine was also primarily responsible for the 
positive interference in the chemiluminescence method under investigation. The 
chemiluminescence responses from the amino acids, tyrosine, histidine, serine, 
threonine, methionine and glycine were between 0.2% and 0.02% of the arginine 
response, and all others tested were below 0.02%. Calibration graphs for urea and 
arginine, prepared using the Pulsed-Flow Chemiluminescence Analyser, revealed a 
slightly lower detection limit (6  10-7 M, S/N = 3) for arginine. Raj and co-workers 
recently examined the pre- and post-dialysis concentration of various species in the 
blood of patients with end-stage renal disease [30]. It was reported that arginine levels 
in the blood fell from around 0.11 to 0.09 mM during the 4 hr dialysis treatments. 
This chemiluminescence signal from arginine at these levels is insignificant compared 
to the response recorded for the levels of urea encountered in spent dialysate. Future 
patient trials will include an examination of cases where there is an increased protein 
metabolism or increased arginine intake due to dietary supplementation. 
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Emission Spectra 
The spectral distribution of the chemiluminescence accompanying the reaction of  
urea with hypobromite shown in Figure 3(ii) is in agreement with the data of Stauff 
and Rümmler [17] and Hu and co-workers [24]. Both groups reported a broad 
emission, from 350 nm to at least 700 nm, with a maximum  emission around 510-520 
nm. Hu et al. [24] noted that the distribution of this broad emission was significantly 
effected by the relative quantum efficiency of their photomultiplier tube. The 
maximum emission in the corrected spectrum occurred at a wavelength of around 710 
nm. We observed similar shift in the emission spectrum after multiplication with a 
correction factor (Figures 3(ii) and 3(iii)), but it was difficult to precisely estimate the 
wavelength at which the maximum intensity occurred due to the broad nature of the 
emission, the accompanying amplification of noise with the correction, and the 
dependence of the corrected spectrum on an estimation made to account for the 
baseline drift over the collection time. 
The luminescence accompanying the reaction between L-arginine and hypobromite 
has a similar spectral distribution to that detected for the oxidation of urea (Figures 
3(i) and 3(ii)). Although this is the first report of the emission accompanying this 
reaction, Stauff and Rümmler [17] had described the emission detected during the 
reaction of gelatine or guanidine with hypochlorite, which had a similar spectral 
distribution than that for the reaction of urea with either hypochlorite or hypobromite. 
In the case of gelatine, we assume that this was due to the presence of L-arginine in 
the polypeptide chain. 
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Reaction Mechanism 
The mechanism proposed by Stauff with Schmidkunz [16] and discussed by Stauff 
and Rümmler [17] involved excited species formed by the recombination of OH or 
O2H radicals, which are formed during the halogenation and oxidation of compounds 
containing –CO-NH2, -C(NH)-NH2 and -CONH- groups, as represented by urea, 
guanidine and gelatine.  In light of the new evidence, including the superior emission 
from arginine in comparison with all other amino acids tested, and the relative 
chemiluminescence intensities from the reaction of hypobromite with urea, 
methylurea, thiourea, creatine, guanidine and arginine, the structural requirements for 
an intense emission could be refined to RC(NH2)2, where R is an oxo (O=) or a 
secondary amine (–NH–) group. Hu and associates [24] examined the oxidation of 
urea with hypobromite and tentatively attributed the emission to molecular nitrogen, a 
known product of the reaction. Molecular nitrogen has been proposed as the emitter or 
excited-state intermediate in a number of chemiluminescence reactions [24,31-33], 
but in each case the suggestion has not been supported by conclusive evidence, and 
the spectral distributions recorded for some of these chemiluminescence reactions do 
not coincide [24]. We are currently investigating the light-producing pathway of the 
chemiluminescent reaction between urea and hypobromite, and a number of related 
reactions. 
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Table 1. 
 
Species (10 mM) 
Relative 
Intensity 
 urea 100 
 ammonium chloride 2.4 
 ammonium carbamate 2.2 
 ammonium hydrogen 
carbonate 
2.2 
 uric acid 0.7 
 hydrazine 0.6 
 methylurea 0.5 
 guanidine 0.5 
 thiourea 0.3 
 sulphamide 0.1 
 creatine 0.1 
 methylamine < 0.1 
 hydroxylamine < 0.1 
 formamide < 0.1 
 acetamide < 0.1 
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Table 2. 
Sample Matrix Filtration Urea Concentration / mM 
  (MWCO) Chemiluminescence Enzymatic 
1 plasma none 14.4 5.6 
2 serum none 14.8 5.5 
3 serum 30000 5.9 5.7 
4 serum 10000 5.8 5.7 
 
 24
Figure 2. 
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Figure 3. 
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Figure 1.  Schematic diagram of the (i) 2-line FIA, (ii) pulsed-flow manifold, and 
(iii) 2-line continuous reaction manifold for the collection of emission 
spectra. The instrumentation comprised of (a) solutions propelled with 
peristaltic or syringe pumps, (b) sample introduction via automated 
injection valve, (c) solutions combined at a Y-piece immediately prior to 
(d) a flow-through detector, and (e) the pulsed-flow module supplying 
both solution propulsion and sample introduction. 
Figure 2. The concentration of urea in spent dialysate during a typical dialysis 
treatment, as determined by the urease (open circles) and direct 
chemiluminescence (solid circles) techniques. 
Figure 3. Uncorrected chemiluminescence emission spectra for the reaction of 
hypobromite with (i) arginine and (ii) urea, and (iii) the corrected spectra 
for the oxidation of urea with hypobromite. 
Table 1.  Relative chemiluminescence intensities on reaction with hypobromite 
using the Pulsed-Flow Chemiluminescence Analyser. 
Table 2.  Determination of urea in human blood samples. 
 
